Combining an existing small-molecule protein therapy called tumor necrosis factor related apoptosis-inducing ligand (TRAIL) with focused ultrasound (FUS) can significantly reduce tumor size and ...

The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF ... which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.

There are plenty of things that want to kill you in the Darién Gap. Dehydration, starvation, and getting lost are the least of your worries. The post Inside the Darién Gap, one of the world’s most ...

Who’s been wrestling T-cell acute lymphoblastic leukemia, or T-cell ALL, for two years with one hand, while staving off avascular necrosis and ... alas, trail 30-28 at the break.

Several BACE1 inhibitors have entered into phase I studies, and at least one of these inhibitors has advanced to phase III human trails. Due to various BACE1 ... smooth pursuit eye movements; TACE, ...

TNF Pharmaceuticals (TNFA) announced the initiation of a fully funded Phase 2b clinical trial evaluating oral TNF-alpha inhibitor drug ...

BALTIMORE, February 25, 2025--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed ...

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory ...